X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Divis Laboratories with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs MYLAN (US) - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DIVIS LABORATORIES   MYLAN
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
MYLAN
Dec-14
DIVIS LABORATORIES/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,2223,830-   
Low Rs7842,699-   
Sales per share (Unadj.) Rs153.11,311.3-  
Earnings per share (Unadj.) Rs39.9158.0-  
Cash flow per share (Unadj.) Rs44.6254.3-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs201.8651.9-  
Shares outstanding (eoy) m265.47378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x6.62.5 263.1%   
Avg P/E ratio x25.120.7 121.5%  
P/CF ratio (eoy) x22.512.8 175.2%  
Price / Book Value ratio x5.05.0 99.2%  
Dividend payout %25.00-   
Avg Mkt Cap Rs m266,2661,235,346 21.6%   
No. of employees `0009.725.0 38.9%   
Total wages/salary Rs m4,6870-   
Avg. sales/employee Rs Th4,175.019,846.6 21.0%   
Avg. wages/employee Rs Th481.50-   
Avg. net profit/employee Rs Th1,089.32,390.8 45.6%   
INCOME DATA
Net Sales Rs m40,643496,164 8.2%  
Other income Rs m749-2,892 -25.9%   
Total revenues Rs m41,392493,272 8.4%   
Gross profit Rs m14,460123,398 11.7%  
Depreciation Rs m1,23336,441 3.4%   
Interest Rs m2321,402 0.1%   
Profit before tax Rs m13,95362,663 22.3%   
Minority Interest Rs m0-257 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,3492,635 127.1%   
Profit after tax Rs m10,60459,771 17.7%  
Gross profit margin %35.624.9 143.1%  
Effective tax rate %24.04.2 570.8%   
Net profit margin %26.112.0 216.6%  
BALANCE SHEET DATA
Current assets Rs m40,105436,194 9.2%   
Current liabilities Rs m6,595341,017 1.9%   
Net working cap to sales %82.519.2 429.8%  
Current ratio x6.11.3 475.5%  
Inventory Days Days11978 151.9%  
Debtors Days Days81107 75.2%  
Net fixed assets Rs m19,995114,786 17.4%   
Share capital Rs m53117,546 3.0%   
"Free" reserves Rs m53,0430-   
Net worth Rs m53,574246,643 21.7%   
Long term debt Rs m0368,460 0.0%   
Total assets Rs m61,585993,454 6.2%  
Interest coverage x618.43.9 15,743.8%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x0.70.5 132.1%   
Return on assets %17.38.2 211.2%  
Return on equity %19.824.2 81.7%  
Return on capital %26.113.6 191.5%  
Exports to sales %00-   
Imports to sales %25.20-   
Net fx Rs m24,9850-   
CASH FLOW
From Operations Rs m11,49365,221 17.6%  
From Investments Rs m-11,372-51,435 22.1%  
From Financial Activity Rs m-93-17,186 0.5%  
Net Cashflow Rs m28-3,400 -0.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.27 Rs / USD

Compare DIVIS LABORATORIES With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare DIVIS LABORATORIES With: NOVARTIS  SANOFI INDIA  DISHMAN PHARMA  LUPIN LTD  DR. REDDYS LAB  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 16, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS